Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Structure Therapeutics, Inc. Sponsored ADR (GPCR) just unveiled an announcement.
Structure Therapeutics Inc. has announced promising results from its Phase 2a obesity study, revealing a significant weight loss in participants using their novel oral GLP-1 receptor agonist, GSBR-1290. The study showed a mean weight reduction of 6.2%, with a third of participants losing 10% of their body weight. Additionally, the new tablet formulation of the drug proved effective and well-tolerated, with plans to begin a 36-week Phase 2b obesity study by the end of 2024. This news could signal a breakthrough in non-peptide, small molecule treatments for obesity, positioning Structure Therapeutics as a potential leader in the market.
Learn more about GPCR stock on TipRanks’ Stock Analysis page.
